Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan;81(1):277-280.
doi: 10.1111/all.70083. Epub 2025 Sep 27.

Tezepelumab Targeting Thymic Stromal Lymphopoietin Enhances Steroid Sensitivity in Patients With Severe Asthma

Keita Hirai  1   2   3 , Sekiko Uehara  3 , Toshihiro Shirai  4 , Taisuke Akamatsu  4 , Kunihiko Itoh  3   5
Affiliations

Tezepelumab Targeting Thymic Stromal Lymphopoietin Enhances Steroid Sensitivity in Patients With Severe Asthma

Keita Hirai et al. Allergy. 2026 Jan.
No abstract available

Keywords: asthma; biologics; steroid sensitivity; thymic stromal lymphopoietin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Changes in steroid sensitivity after treatment with tezepelumab and its association with clinical responses. (A) Time course of changes in steroid sensitivity during tezepelumab treatment. The diamond points represent the weighted average and the error bars indicate the standard error. (B) Forest plot showing the standardized regression coefficients [β, 95% confidence interval (CI)], highlighting the relationship between clinical response and changes in steroid sensitivity after tezepelumab administration. ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; BEC, peripheral blood eosinophil count; FeNO, exhaled nitric oxide fraction; FEV1, forced expiratory volume in one second; OCS, oral corticosteroid.
FIGURE 2
FIGURE 2
Differences in gene expression levels (log2‐transformed) in T cells after tezepelumab treatment. (A) The heatmap indicates fold changes from Week 0 (baseline) to Weeks 4, 8, 16, or 24. (B) Time course of changes in gene expression levels. The red line and blue area indicate the mean fold changes from baseline and 95% confidence intervals, respectively. Gray lines indicate individual data.
See this image and copyright information in PMC

References

    1. Caramori G., Nucera F., Mumby S., Lo Bello F., and Adcock I. M., “Corticosteroid Resistance in Asthma: Cellular and Molecular Mechanisms,” Molecular Aspects of Medicine 85 (2022): 100969, 10.1016/j.mam.2021.100969. - DOI - PubMed
    1. Uehara S., Hirai K., Shirai T., Akamatsu T., and Itoh K., “PI3K Pathway Activation in Severe Asthma Is Linked to Steroid Insensitivity and Adverse Outcomes,” Journal of Allergy and Clinical Immunology Global 4, no. 2 (2025): 100439, 10.1016/j.jacig.2025.100439. - DOI - PMC - PubMed
    1. Wechsler M. E., Menzies‐Gow A., Brightling C. E., et al., “Evaluation of the Oral Corticosteroid‐Sparing Effect of Tezepelumab in Adults With Oral Corticosteroid‐Dependent Asthma (SOURCE): A Randomised, Placebo‐Controlled, Phase 3 Study,” Lancet Respiratory Medicine 10, no. 7 (2022): 650–660, 10.1016/S2213-2600(21)00537-3. - DOI - PubMed
    1. Wechsler M. E., Stolz D., Lugogo N. L., et al., “Oral and Inhaled Corticosteroid Dose Reductions With Tezepelumab Versus Placebo in Patients With Severe, Uncontrolled Asthma From Destination,” Journal of Allergy and Clinical Immunology 12, no. 11 (2024): 3128–3131.e2, 10.1016/j.jaip.2024.08.008. - DOI - PubMed
    1. Jackson D. J., Lugogo N., Gurnell M., et al., “Tezepelumab Reduces and Eliminates OCS Use in OCS‐Dependent Patients With Severe Asthma: Primary Results From the Phase 3b WAYFINDER Study,” American Journal of Respiratory and Critical Care Medicine 211, no. Abstracts (2025): A5231, 10.1164/ajrccm.2025.211.Abstracts.A5231. - DOI

LinkOut - more resources